WC
CLVS

Wexford Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Wexford Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,568
Closed -$36K – 391
2020
Q4 		$36K Buy
+7,568
New +$38.3K 0.01% 286
2017
Q3 		– Sell
-3,900
Closed -$365K – 203
2017
Q2 		$365K Buy
+3,900
New +$239K 0.03% 127

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wexford Capital's CLVS Position: Q1 2021 in Review

Wexford Capital sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 7,568 shares — an estimated $36K sold.

Wexford Capital first reported a position in CLVS in Q2 2017 and held it in 2 quarters. The position peaked at $365K in Q2 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

  • Wexford Capital reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 7,568 Clovis Oncology, Inc. shares in Q1 2021, an estimated $36K.
  • Wexford Capital first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 2 quarters.
  • Wexford Capital's Clovis Oncology, Inc. position peaked at $365K in Q2 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.